Literature DB >> 9138295

High rate of seroconversion following administration of a single supplementary dose of recombinant hepatitis B vaccine in Iranian healthy nonresponder neonates.

F Shokri1, A Amani.   

Abstract

Forty-nine Iranian neonates who failed to develop a protective anti hepatitis B surface antigen (HBs) response following primary vaccination with triple doses of recombinant hepatitis B vaccine, were classified as hypo-responders (anti-HBs > 1 < 10 IU/l) or non-responders (anti-HBs < 1 IU/l) and subsequently challenged with a single supplementary vaccine dose. A protective and anamnestic type of response was observed in 90% (44/49) of the neonates. The mean titer of anti-HBs antibody was significantly higher following supplementary vaccination, compared to that achieved after primary vaccination. This was more evident in the primary hypo-responder neonates (P < 0.00001) than the non-responder group (P < 0.002). The results indicate that a significant proportion of the non-responder neonates to HBs antigen can be induced to develop a protective and long-lasting antibody response by administration of a single additional vaccine dose.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138295     DOI: 10.1007/s004300050035

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  3 in total

1.  The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates.

Authors:  A Jafarzadeh; F Shokri
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

2.  Revaccination of non-responding infants delivered by HBsAg-positive mothers.

Authors:  M R Hasanjani Roushan; Y Zahed Pasha; R Saghebi; F Kohi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

3.  Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen.

Authors:  M A Shokrgozar; F Shokri
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.